R-flurbiprofen suppresses distal nonmucin-producing colorectal tumors in azoxymethane-treated rats, without suppressing eicosanoid production

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 298, Issue 6, 2010, Pages

  Martin, Jonathan E ^a,b   Le Leu, Richard K ^b   Hu, Ying ^b   Young, Graeme P ^b  

^a REPATRIATION GENERAL HOSPITAL   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

Author keywords

Colon cancer; Nonsteroidal anti inflammatory drugs; Sulindac

Indexed keywords

AZOXYMETHANE; FLURBIPROFEN; ICOSANOID; MUCIN; PROSTAGLANDIN E2; SULINDAC;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASPIRIN EXACERBATED RESPIRATORY DISEASE; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL ASSESSMENT; COLORECTAL CANCER; COLORECTAL TUMOR; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG MECHANISM; DRUG TOLERABILITY; FEEDING; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; TUMOR CLASSIFICATION; TUMOR LOCALIZATION; TUMOR VOLUME; WEIGHT GAIN;

ANIMALS; ANTINEOPLASTIC AGENTS; AZOXYMETHANE; CARCINOGENS; COLORECTAL NEOPLASMS; DINOPROSTONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EICOSANOIDS; FLURBIPROFEN; MALE; MUCINS; RATS; RATS, SPRAGUE-DAWLEY; SULINDAC;

EID: 77952699240     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00330.2009     Document Type: Article

References (32)

1. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348: 891-899, 2003. (Pubitemid 36297997)
2. Chan AT, Giovannucci EL, Schernhammer ES, Colditz GA, Hunter DJ, Willett WC, Fuchs CS. A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med 140: 157-166, 2004.
3. Charalambous D, O'Brien PE. Inhibition of colon cancer precursors in the rat by sulindac sulphone is not dependent on inhibition of prostaglandin synthesis. J Gastroenterol Hepatol 11: 307-310, 1996. (Pubitemid 26142924)
4. Charalambous D, Skinner SA, O'Brien PE. Sulindac inhibits colorectal tumour growth, but not prostaglandin synthesis in the rat. J Gastroenterol Hepatol 13: 1195-1200, 1998. (Pubitemid 29029950)
5. Corpet DE, Pierre F. Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 12: 391-400, 2003. (Pubitemid 36578475)
6. Galasko DR, Graff-Radford N, May S, Hendrix S, Cottrell BA, Sagi SA, Mather G, Laughlin M, Zavitz KH, Swabb E, Golde TE, Murphy MP, Koo EH. Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis Assoc Disord 21: 292-299, 2007. (Pubitemid 350307433)
7. Geisslinger G, Lotsch J, Menzel S, Kobal G, Brune K. Stereoselective disposition of flurbiprofen in healthy subjects following administration of the single enantiomers. Br J Clin Pharmacol 37: 392-394, 1994. (Pubitemid 24204605)
8. Ghirardi M, Nascimbeni R, Villanacci V, Fontana MG, Di Betta E, Salerni B. Azoxymethane-induced aberrant crypt foci and colorectal tumors in F344 rats: sequential analysis of growth. Eur Surg Res 31: 272-280, 1999. (Pubitemid 29261371)
9. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, Speizer FE. Aspirin and the risk of colorectal cancer in women. N Engl J Med 333: 609-614, 1995. (Pubitemid 26017942)
10. Hu Y, Le Leu RK, Young GP. Defective acute apoptotic response to genotoxic carcinogen in small intestine of APC(Min/+) mice is restored by sulindac. Cancer Lett 248: 234-244, 2007. (Pubitemid 46330556)
11. Hu Y, Le Leu RK, Young GP. Sulindac corrects defective apoptosis and suppresses azoxymethane-induced colonic oncogenesis in p53 knockout mice. Int J Cancer 116: 870-875, 2005. (Pubitemid 41209192)
12. Hu Y, Martin J, Young G. NSAID enhancement of the apoptotic response to a colon carcinogen is independent of COX inhibition (Abstract). J Gastroenterol Hepatol 15: J73, 2000.
13. Hu Y, McIntosh GH, Le Leu RK, Woodman R, Young GP. Suppression of colorectal oncogenesis by selenium-enriched milk proteins: apoptosis and K-ras mutations. Cancer Res 68: 4936-4944, 2008.
14. Imperiale TF. Aspirin and the prevention of colorectal cancer. N Engl J Med 348: 879-880, 2003.
15. Iwama T. NSAIDs and colorectal cancer prevention. J Gastroenterol 44, Suppl 19: 72-76, 2009.
16. Kishimoto Y, Yashima K, Morisawa T, Ohishi T, Marumoto A, Sano A, Idobe-Fujii Y, Miura N, Shiota G, Murawaki Y, Hasegawa J. Effects of long-term administration of sulindac on APC mRNA and apoptosis in colons of rats treated with azoxymethane. J Cancer Res Clin Oncol 128: 589-595, 2002. (Pubitemid 35435555)
17. Le Leu RK, Young GP, McIntosh GH. Folate deficiency reduces the development of colorectal cancer in rats. Carcinogenesis 21: 2261-2265, 2000.
18. Liu T, Mokuolu AO, Rao CV, Reddy BS, Holt PR. Regional chemoprevention of carcinogen-induced tumors in rat colon. Gastroenterology 109: 1167-1172, 1995.
19. Loveridge CJ, MacDonald AD, Thoms HC, Dunlop MG, Stark LA. The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-kappaB. Oncogene 27: 2648-2655, 2008.
20. Park HS, Goodlad RA, Wright NA. The incidence of aberrant crypt foci and colonic carcinoma in dimethylhydrazine-treated rats varies in a sitespecific manner and depends on tumor histology. Cancer Res 57: 4507-4510, 1997.
21. Pereira MA, Barnes LH, Steele VE, Kelloff GV, Lubet RA. Piroxicam-induced regression of azoxymethane-induced aberrant crypt foci and prevention of colon cancer in rats. Carcinogenesis 17: 373-376, 1996.
22. Piazza GA, Alberts DS, Hixson LJ, Paranka NS, Li H, Finn T, Bogert C, Guillen JM, Brendel K, Gross PH, Sperl G, Ritchie J, Burt RW, Ellsworth L, Ahnen DJ, Pamukcu R. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 57: 2909-2915, 1997. (Pubitemid 27315038)
23. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348: 883-890, 2003. (Pubitemid 36297996)
24. Smalley W, Ray WA, Daugherty J, Griffin MR. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 159: 161-166, 1999.
25. Stoner GD, Budd GT, Ganapathi R, DeYoung B, Kresty LA, Nitert M, Fryer B, Church JM, Provencher K, Pamukcu R, Piazza G, Hawk E, Kelloff G, Elson P, van Stolk RU. Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Adv Exp Med Biol 470: 45-53, 1999.
26. Sunter JP, Appleton DR, Wright NA, Watson AJ. Pathological features of the colonic tumours induced in rats by the administration of 1,2-dimethylhydrazine. Virchows Arch B Cell Pathol 29: 211-223, 1978.
27. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94: 252-266, 2002.
28. van Stolk R, Stoner G, Hayton WL, Chan K, DeYoung B, Kresty L, Kemmenoe BH, Elson P, Rybicki L, Church J, Provencher K, McLain D, Hawk E, Fryer B, Kelloff G, Ganapathi R, Budd GT. Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin Cancer Res 6: 78-89, 2000.
29. Ward JM, Yamamoto RS, Brown CA. Pathology of intestinal neoplasms and other lesions in rats exposed to azoxymethane. J Natl Cancer Inst 51: 1029-1039, 1973.
30. Wechter WJ, Kantoci D, Murray ED Jr, Quiggle DD, Leipold DD, Gibson KM, McCracken JD. R-flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC(Min)/+ mouse model: implications for prophylaxis and treatment of colon cancer. Cancer Res 57: 4316-4324, 1997.
31. Wechter WJ, Murray ED Jr, Kantoci D, Quiggle DD, Leipold DD, Gibson KM, McCracken JD. Treatment and survival study in the C57BL/6J-APC(Min)/+(Min) mouse with R-flurbiprofen. Life Sci 66: 745-753, 2000.
32. Williams CS, Goldman AP, Sheng H, Morrow JD, DuBois RN. Sulindac sulfide, but not sulindac sulfone, inhibits colorectal cancer growth. N Engl J Med 1: 170-176, 1999.